

Friday

December 14th

2 0 1 8

08:45-09:00 Opening Remarks
Kostas Syrigos
Erdem Goker
Fred Hirsch
Yesim Eralp

09:00-10:30 Turkish Prospect for the Fight Against Tobacco & Asbestosis

Registry / Trials in Thoracic Cancers

Chairs: **Celalettin Kocaturk & Ioannis Gkiozos**

09:00-09:15 National efforts for a smoke-free environment **Elif Dagli**
 09:15-09:30 National asbestosis map **Hasan Fevzi Batirel**
 09:30-09:40 High risk screening program initiative: Single institution experience **Celalettin Kocaturk**
 09:40-10:00 Identification of high-risk populations for lung cancer screening programs **Ioannis Gkiozos**
 10:00-10:15 Potential role of exhaled breath analysis for lung cancer screening **Erdem Goker**
 10:15-10:30 Discussion

10:30-11:05 Coffee Break

11:05-12:30 Recent Advances in Thoracic Tumors

IASLC 2018 & Year in Review

Chairs: **Fred Hirsch & Ilgaz Dogusoy**

11:05-11:25 Advances in surgical management strategies **Jessica Donington**
 11:25-11:45 Advances in radiation oncology **Ugur SeleK**
 11:45-12:05 Advances in systemic treatment **Heather Wakelee**
 12:05-12:30 Discussion

12:30-13:30 Lunch

13:30-15:10 Early stage NSCLC: Advances in optimal therapeutic options and integration of novel approaches in management strategies

Chairs: **Sofia Agelaki & Nalan Akyürek**

13:30-13:45 Pitfalls in pathologic evaluation with small or cytologic samples **Buge Oz**
 Discussion
 13:50-14:10 Controversies in the optimal use of adjuvant chemotherapy: Critical decision making in high risk stage 1B tumors & biologic agents **Basak Oyan Uluc**
 Discussion
 14:15-14:30 Role of targeted therapy and immune check-point inhibitors in the neoadjuvant setting **Heather Wakelee**
 Discussion
 14:35-14:55 Integration of biologic agents and immunotherapy in the radical treatment of unresectable stage III non-small cell lung cancer **Johan Vansteenkiste**



Discussion

15:10-15:30 Coffee Break**15:30-18:00 Live Tumor Board / Case Discussion***Optimal Treatment Strategies in Early and Locally Advanced Non-small Cell Lung Cancer*Chairs: **Robert Pirker & Nil Molinas Mandel & Fulden Yumuk**

Panel:

Pneumology

Radiology

Pathology

Surgery

Radiation Oncology

Medical Oncology

Andriani Charpidou**Nihat Kodalli****Dilek Yilmazbayhan****Jessica Donington****Fazilet Dincbas****Adnan Aydiner**

Discussion points:

Optimal treatment strategies in localized disease**Stage III NSCLC and Neo-adjuvant treatment**

- The role of irradiation in the neoadjuvant setting for stage III NSCLC
- Optimal use of surgery in stage III NSCLC incl salvage surgery
- Role of targeted therapy and immune check-point inhibitors in the neoadjuvant setting
- Role of SBRT in medically inoperable early stage NSCLC: National Experience of the Turkish Radiation Oncology Association

Banu Atalar (IASLC 2018 Awardee)

Saturday

December 15th

2 0 1 8



09:00-10:20 Controversies in Integration of Diagnostic Methods for Personalized Oncology

Chairs: **Handan Zeren & Katarina Politi**

09:00-09:20 Liquid biopsies in daily practice pitfalls in the real-life setting (tissue-serum discordance) and how they could be optimally used to guide treatment selection **Huseyin Baloglu**

09:20-09:40 Optimal use of biomarkers to predict for efficacy of immune checkpoint inhibitors **Fred Hirsch**

09:40-10:10 Discussion

10:10-10:40 Coffee Break

10:40-12:30 Treatment of Advanced Non-small Cell Lung Cancer

Chairs: **Ahmet Demirkazik & Ilhan Oztop**

10:40-11:00 Optimal sequencing in EGFR mutant NSCLC **Mustafa Erman**

11:00-11:20 Optimal management and sequencing for NSCLC with ALK & ROS transusions **Fabrice Barlesi**

11:20-11:40 Advances in management for rare mutations: KRAS and beyond **Vassiliki Papadimitrakopoulou**

11:40-12:00 Discussion

12:00-12:20 Treatment of non-mutation driven tumors **Christoph Zielinski**

12:20-12:30 Discussion

12:30-13:15 Lunch

13:15-14:10 Recent Advances in Thoracic Malignant Diseases Beyond NSCLC

IASLC 2018 & Year in Review

Chairs: **Levent Elbeyli & Muge Akmansu**

13:15-13:35 Mesothelioma & Thymoma **Elias Kotteas**

13:35-13:55 Small Cell Lung Cancer and Neuroendocrine tumors **Fatih Selcukbiricik**

13:55-14:10 Discussion

14:10-14:30 Coffee Break

14:30-15:15 Thoracic Oncology in the Geriatric Population: Round Table Discussion

Chairs: **Dimitris Kardamakis & Aziz Karaoglu & Seref Komurcu**

- Treating lung cancer in the elderly with radiotherapy
- Evaluation and management of the elderly patient with targeted therapy and chemotherapy
- Evolving role of immunotherapy in the elderly patient with lung cancer: Strategies to optimize treatment and practical tips

15:15-16:00 Management of Toxicity with IO's and Combinations: Case-based Panel

Chairs: **Sofia Tsagkouli & Mehmet Altan & Hande Turna**

- Evaluation and management strategies for suspected immune mediated organ injury
- Management of patients with special pre-existing conditions: Rheumatologic diseases and transplant patients
- Toxicity and management with combinations including IO's

16:00-16:15 Coffee Break

16:15-18:30 Live Tumor Board / Case Discussion

*Optimal Treatment Strategies in Advanced
Non-small Cell Lung Cancer*

Chairs: **Erdem Goker & Heather Wakelee & Yesim Eralp**

Panel:

Pneumology
Radiology
Pathology
Surgery
Radiation Oncology
Medical Oncology

**Benan Caglayan
Cagatay Cimsit
Nalan Akyürek
Serhan Tanju
Muge Akmansu
Robert Pirker**

Discussion points:

- Integration of local treatment approaches in the advanced disease setting
- Optimal use of systemic treatment in mutation-driven and non-mutation harboring tumors
- Guidance to implement sustainable cancer care in a real-world setting

Robert Pirker

Immuno-oncology

- Optimal use of immune checkpoint inhibitors in the 1st line setting
- Abscopal effect of irradiation and combined use with immuno-oncology
- Tackling resistance: Optimizing immuno-oncology with combinations of targeted agents and chemotherapy

18:30-18:45 Concluding Remarks

**Yesim Eralp
Kostas Syrigos**